Q3 2025 TG Therapeutics Inc Earnings Call Transcript
Key Points
- TG Therapeutics Inc (TGTX) reported strong financial performance with total revenue reaching $161.7 million, a 93% increase compared to Q3 2024.
- BRIUMVI, the company's flagship product for relapsing MS, continues to outperform expectations with US net sales totaling approximately $153 million in Q3.
- The company completed enrollment for the ENHANCE study, which aims to simplify BRIUMVI's dosing schedule, with data expected by mid-next year.
- TG Therapeutics Inc (TGTX) is financially disciplined, completing a $100 million share repurchase program and authorizing another $100 million program.
- The company achieved its sixth consecutive quarter of profitability, driven by BRIUMVI revenue growth and disciplined expense management.
- The updated revenue guidance for Q4 implies a slight slowing of sequential growth compared to prior years.
- Operating expenses increased in Q3 due to continued investment in R&D and higher SG&A spend, though the company remains on track to meet full-year OpEx guidance.
- The competitive dynamics in the subcutaneous market segment are challenging, with existing competitors showing growth.
- There is uncertainty regarding the impact of direct-to-consumer efforts on long-term patient conversions and growth.
- The company has not pursued certain business development deals due to high ROI thresholds and risk-reward considerations, potentially limiting immediate portfolio expansion.
Greetings, and welcome to the TG Therapeutics' third quarter earnings call and webcast. (Operator Instructions) Please note, this conference is being recorded.
I will now turn the conference over to your host, Jenna Bosco, Chief Communications Officer. Please go ahead.
Thank you. Welcome, everyone, and thank you for joining us this morning. I'm Jenna Bosco, and with me to discuss TG Therapeutics' third quarter 2025 financial results are Michael Weiss, our Chairman and Chief Executive Officer; Adam Waldman, our Chief Commercial Officer; and Sean Power, our Chief Financial Officer. Following our Safe Harbor statement, Mike will begin with an overview of our recent corporate developments. Adam will provide an update on our commercial efforts, and Sean will review our financial results before we open the call for Q&A.
Before we begin, I would like to remind everyone that today's discussion will include forward-looking statements within the meaning of the Private Securities
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
